2018 AANS Annual Scientific Meeting-558. P2Y12 Precision in Therapeutic Monitoring of Dual Anti-Platelet Therapy for Flow Diversion of Cerebral Aneurysms

558. P2Y12 Precision in Therapeutic Monitoring of Dual Anti-Platelet Therapy for Flow Diversion of Cerebral Aneurysms

Video Transcription

Video Summary

In this video, neurosurgery resident Dr. Matt Bender discusses the precision of VerifyNow P2Y12 assessment of clopidogrel response in patients undergoing cerebral aneurysm flow diversion. He explains that dual antiplatelet therapy with aspirin and Plavix is standard in intracranial stenting procedures. However, there is significant variability in clopidogrel response due to genetics and other factors. Dr. Bender presents the results of a study conducted at Johns Hopkins, which showed that within 24 hours, a quarter of patients had a variation in PRU (platelet reactivity unit) of nearly 50 points or greater. He also discusses the mixed results of antiplatelet therapy tailoring and suggests the need for optimized diagnostics and potential use of P2Y12 inhibitors.

Asset Caption

Matt Bender, MD

Keywords

neurosurgery resident

VerifyNow P2Y12 assessment

clopidogrel response

cerebral aneurysm flow diversion

dual antiplatelet therapy